V. S. S. Abhinav Ayyadevara

V. S. S. Abhinav Ayyadevara

Auto-generated profile, based on publicly available information

V. S. S. Abhinav Ayyadevara

Department of Basic Science, Division of Cancer Sciences, Loma Linda University School of Medicine, Loma Linda, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Drug Delivery
Verified
Journal Article
Open access
VAV. S. S. Abhinav Ayyadevara
V. S. S. Abhinav Ayyadevara
KRKyung-Ho Roh
Kyung-Ho Roh
Jurkat, an immortalized cell line derived from human leukemic T lymphocytes, has been employed as an excellent surrogate model of human primary T-cells for the advancement of T-cell biology and their applications in medicine. However, presumably due to its T-cell origin, Jurkat cells are very difficult to transfect. Thus, for the genetic modification of Jurkat cells, expensive and time-consuming viral vectors are normally required. Despite many previous efforts, non-viral vectors have not yet overcome the hurdles of low transfection efficiency and/or high toxicity in transfection of Jurkat cells. Here, we report that a simple addition of calcium ions (Ca2+) into culture media at optimal concentrations can enhance the efficiency of the polyplex-mediated transfection using poly(ethylene imine) (PEI) by up to 12-fold when compared to the polyplex-only control. We show that calcium enhances the association between polyplex and Jurkat, which is at least partially responsible for the increase in transmembrane delivery of polyplex and consequential enhancement in expression of transgene. Other cations, Mg2+ or Na+ did not show similar enhancement. Interestingly, addition of Ca2+ was rather detrimental for the transfection of lipoplex on Jurkat cells. Observation of significant enhancement in the transfection of non-viral vectors with a simple and physiologically relevant reagent like Ca2+ in the engineering of hard-to-transfect cells such as Jurkat warrants further investigation on similar strategies.

27 March 2025 in Leukemia
Verified
Journal Article
Open access
PDF file
VAV. S. S. Abhinav Ayyadevara
V. S. S. Abhinav Ayyadevara
GWGerald Wertheim
Gerald Wertheim
SGShikha Gaur
Shikha Gaur
JCJohn A. Chukinas
John A. Chukinas
JLJoseph P. Loftus
Joseph P. Loftus
CHChristian Hurtz
Christian Hurtz
Unbiased kinome-wide CRISPR screening identified DYRK1A as a potential therapeutic target in KMT2A-rearranged (KMT2A-R) B-acute lymphoblastic leukemia (ALL). Mechanistically, we demonstrate that DYRK1A is regulated by the KMT2A fusion protein and affects cell proliferation by regulating MYC expression and ERK phosphorylation. We further observed that pharmacologic DYRK1A inhibition markedly reduced human KMT2A-R ALL cell proliferation in vitro and potently decreased leukemia proliferation in vivo in drug-treated patient-derived xenograft mouse models. DYRK1A inhibition induced expression of the proapoptotic factor BIM and reduced the expression of BCL-XL, consequently sensitizing KMT2A-R ALL cells to BCL2 inhibition. Dual inhibition of DYRK1A and BCL2 synergistically decreased KMT2A-R ALL cell survival in vitro and reduced leukemic burden in mice. Taken together, our data establishes DYRK1A as a novel therapeutic target in KMT2A-R ALL and credential dual inhibition of DYRK1A and BCL2 as an effective translational therapeutic strategy for this high-risk ALL subtype.

12 January 2021 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
AAArmin Ahmadi
Armin Ahmadi
VAV. S. S. Abhinav Ayyadevara
V. S. S. Abhinav Ayyadevara
JBJerome Baudry
Jerome Baudry
KRKyung-Ho Roh
Kyung-Ho Roh
CD3ε is expressed on T lymphocytes as a part of the T cell receptor (TCR)-CD3 complex. Together with other CD3 molecules, CD3ε is responsible for the activation of T cells via transducing the event of antigen recognition by the TCR into intracellular signaling cascades. The present study first aims to identify a novel peptide ligand that binds to human CD3ε in a specific manner and to perform an initial evaluation of its biological efficacy on the human T cell line, Jurkat cells. We screened a phage-display peptide library against human CD3ε using a subtractive biopanning process, from which we identified 13 phage clones displaying unique peptide sequences. One dominant phage clone displaying the 7 amino acid sequence of WSLGYTG, which occupied 90% of tested plaques (18 out of 20) after the 5th round of biopanning, demonstrated a superior binding behavior to other clones in the binding assays against recombinant CD3ε on microbeads or Jurkat cells. The synthesized peptide also showed specific binding to Jurkat cells in a dose-dependent manner but not to B cell lymphoma line, 2PK3 cells. Molecular modeling and docking simulation confirmed that the selected peptide ligand in an energetically stable conformation binds to a pocket of CD3ε that is not hidden by either CD3γ or CD3δ. Lastly, magnetic microbeads conjugated with the synthesized peptide ligands showed a weak but specific association with Jurkat cells and induced the calcium flux, a hallmark indication of proximal T cell receptor signaling, which gave rise to an enhancement of IL-2 section and cell proliferation. The novel peptide ligand and its various multivalent forms have a great potential in applications related to T cell biology and T cell immunotherapy.

8 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
MCMarissa L. Calbert
Marissa L. Calbert
GCGurushankar Chandramouly
Gurushankar Chandramouly
CAClare M. Adams
Clare M. Adams
MSMagali Saez-Ayala
Magali Saez-Ayala
TKTatiana Kent
Tatiana Kent
RPRichard Pomerantz
Richard Pomerantz
Anticancer nucleosides are effective against solid tumors and hematologic malignancies, but typically are prone to nucleoside metabolism resistance mechanisms. Using a nucleoside-specific multiplexed high-throughput screening approach, we discovered 4′-ethynyl-2′-deoxycytidine (EdC) as a third-generation anticancer nucleoside prodrug with preferential activity against diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires deoxycytidine kinase (DCK) phosphorylation for its activity and induces replication fork arrest and accumulation of cells in S-phase, indicating it acts as a chain terminator. A 2.1Å cocrystal structure of DCK bound to EdC and UDP reveals how the rigid 4′-alkyne of EdC fits within the active site of DCK. Remarkably, EdC was resistant to cytidine deamination and SAMHD1 metabolism mechanisms and exhibited higher potency against ALL compared with FDA-approved nelarabine. Finally, EdC was highly effective against DLBCL tumors and B-ALL in vivo. These data characterize EdC as a preclinical nucleoside prodrug candidate for DLBCL and ALL.

10 July 2026 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
ACAshlyn Conant
Ashlyn Conant
TSTise Suzuki
Tise Suzuki
KMKiera McGivney
Kiera McGivney
VAV. S. S. Abhinav Ayyadevara
V. S. S. Abhinav Ayyadevara
SASharon Asariah
Sharon Asariah
JUJuli Unternaehrer
Juli Unternaehrer
Type 1 interferon (IFN‐1) production and signaling are frequently activated in response to DNA damage and have been associated with the development of therapy resistance in cancer. However, the cell‐autonomous role of IFN‐1 in driving resistance in high‐grade serous ovarian cancer (HGSOC) remains unclear. Specifically, whether IFN‐1 functions in HGSOC as solely a response to genotoxic stress due to genotoxic therapy as frontline treatment, or can independently act in driving resistance phenotypes, has not been studied. Utilizing a patient‐derived model of cisplatin‐sensitive (SE) and ‐resistant (CR) HGSOC, we demonstrate that chronic cisplatin exposure is associated with enrichment of IFN‐1 signaling and an interferon‐related DNA damage resistance signature. Acute cisplatin treatment elicited dynamic IFN‐1 signaling in both SE and CR cells, indicating a conserved stress response. However, chronic, low‐level exposure to exogenous IFNβ, without a DNA‐damaging agent, phenocopied several features of chronic cisplatin‐driven resistance, including reduced therapeutic sensitivity and decreased proliferation. Together, these findings identify IFNβ as a driver of resistance‐associated phenotypes and highlight cell‐autonomous IFN‐1 signaling as a potential biomarker for resistance and therapeutic target in platinum‐resistant disease.

28 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAshlyn Conant
Ashlyn Conant
TSTise Suzuki
Tise Suzuki
KMKiera McGivney
Kiera McGivney
VAV S S Abhinav Ayyadevara
V S S Abhinav Ayyadevara
SASharon Asariah
Sharon Asariah
JUJuli Unternaehrer
Juli Unternaehrer
Cancer cell-autonomous type 1 interferon (IFN-1) production and signaling is frequently activated in response to DNA damage and has been associated with the development of therapy resistance in several cancer types. However, its cell-autonomous role in driving resistance in high-grade serous ovarian cancer (HGSOC), a disease defined by near-universal exposure to genotoxic therapy as frontline treatment, remains unclear. Specifically, whether IFN-1 functions in HGSOC as only a response to genotoxic stress or can independently act in driving resistance phenotypes has not been studied. Utilizing a syngeneic patient-derived model of cisplatin-sensitive (SE) and -resistant (CR) HGSOC, we demonstrate that chronic cisplatin exposure is associated with enrichment of IFN-1 signaling and the interferon-related DNA damage resistance signature (IRDS). Acute cisplatin treatment elicited dynamic, temporal IFN-1 signaling and responses in both sensitive and resistant cells, indicating a conserved stress response in resistant cells. Chronic, low-level exposure to exogenous IFNβ, in the absence of a DNA-damaging agent, was sufficient to phenocopy several features of chronic cisplatin driven resistance, including reduced therapeutic sensitivity, cell cycle arrest, and decreased proliferation. Notably, IFNβ driven resistance occurred without sustained IRDS or canonical interferon stimulated gene (ISG) induction, revealing alternative mechanisms for IFN-1 mediated therapy resistance. Together, these findings identify IFNβ as a functional driver of the development of resistance-associated phenotypes and highlight cell-autonomous IFN-1 signaling as a potential biomarker for resistance and a therapeutic target in platinum-resistant disease.